Form 4: Provectus Biopharmaceuticals CFO Acquires Stock Options

Provectus Biopharmaceuticals' CFO, Heather Raines, was granted 4,197,890 stock options on December 2, 2024.

Summary

• Heather Raines, the CFO of Provectus Biopharmaceuticals, Inc., was granted 4,197,890 stock options on December 2, 2024.
• These options have an exercise price of $0.2862 per share.
• The options vest in three equal annual installments starting on December 2, 2024.
• The options expire on December 2, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.

Positives

• The grant of stock options to the CFO aligns her interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Risks

• The value of the options is dependent on the future performance of the company's stock price.
• If the stock price does not increase above the exercise price, the options will have no value.

Future Outlook

The stock options will vest over the next three years, incentivizing the CFO to contribute to the company's long-term success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The vesting schedule of three years is also typical for such grants.
• The exercise price of $0.2862 is specific to the company's current stock price and market conditions.

Stakeholder Impact

• Shareholders may view this positively as it aligns the CFO's interests with the company's performance.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, CFO, Provectus Biopharmaceuticals, equity, insider trading, executive compensation